압타바이오

293780KOSDAQSector: Pharma & Biotech

₩4,145▲ 0.85%Market cap ₩116.4BAs of Jul 21, 2026 close · updated once daily

Grade C42.3 ptsTop 67% of 2,523 stocks

Financial strength

42.0

Growth momentum

61.0

Price attractiveness

29.3

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

42.0

How much debt does it carry relative to equity?

Debt-to-equity ratio

27.2%

✓ Above median · Top 26.6% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

260.9%

✓ Above median · Top 38% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-428.4%

✗ Below median · Top 89.9% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

-34.6%

✗ Below median · Top 77.4% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Growth momentum

61.0

How much did revenue grow in a year?

Revenue growth (YoY)

10.0%

✓ Above median · Top 38.6% in sector

Sector median 6.4%

Did core profits grow in a year?

Operating income change (YoY)

16.0%

✓ Above median · Top 39.5% in sector

Sector median 3.6%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

29.3

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✗ Below median · Top 75.8% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

2.47x

✗ Below median · Top 65.7% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15